/Investor DB

BIOSPRING PARTNERS — Full Portfolio

11 tracked investments · listed companies and verified rows first

Kinicitikiniciti.cominNov 2021✓ verified

Kiniciti is a platform company that operates cell and gene therapy-focused life science businesses, including Cellistic for iPSC-based manufacturing technologies and Ncardia for human iPSC products and drug discovery services.

BiotechDeep TechHealthtechMedical Devices

Geoffrey Glass(Founding CEO)in

Co-investorsWelsh, Carson, Anderson & StoweWCAS

Labvivalabviva.cominSeries A · Jan 2025 · $25M✓ verified

Labviva is an AI-native procurement platform that unifies the life sciences supply chain, helping research organizations optimize procurement processes and reduce costs.

AI & Machine LearningBiotechEnterprise SoftwareSaaSCambridge, US

Siamak Baharloo(Executive Officer, Director)inCarlo(GM of Europe)inNick Premnath(SVP of Commercial Strategy)inAaron Miramontes(Executive Officer)Nicholas Rioux(Executive Officer, Director)in

BoardSarah Fay(Director)in

Co-investorsGlasswing VenturesVillage Global53 StationsB Capital GroupB4 CapitalMassVentures

Abzenaabzena.comin𝕏Mar 2022 · $65M

Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs.

Advanced ManufacturingBiotechHealthtechMedical DevicesCambridge, US

William John Edward Burt(Executive Officer, Director)Nigel Pitchford(Director)Leigh Pierce(Executive Officer)Kenneth Cunningham(Director)Julian Smith(Executive Officer, Director)Anthony Brampton(Director)

Co-investorsBeringeaWCASWelsh, Carson, Anderson & Stowe

Cedarhealthresearchcedarhealthresearch.comin𝕏

Cedar Health Research operates clinical research services for community-based healthcare providers, connecting patient populations with clinical trials through partnerships and EMR abstraction technology.

BiotechHealthtechMedical DevicesDallas, US

Mimi Fenton(Chief Executive Officer)

Cenexelcenexelresearch.com

CenExel operates a network of clinical research centers that conduct trials and studies to advance new medical treatments.

BiotechHealthtechMedical Devices

Co-investorsBayPineOwl Rock Capital

Ixlayerixlayer.comin𝕏Series A · Mar 2021 · $75M

ixlayer provides a platform that connects biopharma companies with patients, labs, providers, and payment systems to deploy personalized patient experience programs powered by AI.

AI & Machine LearningDigital HealthHealthtechSaaS

Pouria Sanae(Founder)inPoorya Sabounchi(Co-founder and Chief Operating Officer)in

Co-investorsInitiate Venture PartnersNimble PartnersPlug and Play VenturesXYZ Venture CapitalGeneral CatalystMBX Capital

Path Aipathai.com

AI-powered pathology for improved patient outcomes

Boston, US

ANDREW BECK(Executive Officer, Director)inADITYA KHOSLA(Executive Officer, Director)Aditya Khosla(Founder)Andy Beck(Chief Executive Officer, Co-founder)

BoardMICHELLE DIPP(Director)STANLEY LAPIDUS(Director)in

Co-investors8VCFairhaven Capital PartnersGeneral AtlanticGeneral CatalystHighsage VenturesMerck Global Health Innovation Fund+7 more

Reasonerreasoner.comPre-Seed · Jun 2023

Reasoner analyzes thousands of human behavioral and psychological signals — including what people say, choose, value, and avoid — to identify patterns unique to each individual.

AI & Machine LearningDeep Tech

Co-investorsAlumni VenturesBoston Seed CapitalOperator Collective186 VenturesAccompliceBaseline Ventures+5 more

Rocheroche.com

Roche is a healthcare company that develops diagnostics and pharmaceuticals aimed at preventing, treating, and curing diseases.

BiotechDigital HealthHealthtechBasel, CH

Thomas Schinecker(CEO)in

Co-investorsAllen & CompanyAlphabetFirst Round CapitalGV (Google Ventures)SV Angel

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

InfringementsInvalidate

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.